Gene Therapy for ACM Due to a PKP2 Pathogenic Variant
Oct 25, 2023
―
Low Dose Lx2006, Mid Dose Lx2006, High Dose Lx2006
Friedreich Ataxia, Cardiomyopathy, Secondary
Phase I/II
Active Not Recruiting
Gene Therapy for Cardiomyopathy Associated With Friedreich's Ataxia
Jun 23, 2022
―
Lx1001
Alzheimer Disease
Phase I
Active Not Recruiting
Long-Term Follow-up of Gene Therapy for APOE4 Homozygote Alzheimer's Disease
May 27, 2022
―
Lx1001
Alzheimer Disease, Early Onset Alzheimer Disease
Phase I/II
Completed
Gene Therapy for APOE4 Homozygote of Alzheimer's Disease
Aug 03, 2018
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Lexeo Therapeutics, Inc. (LXEO) have in its pipeline
LXEO is currently developing the following drugs: Lx2020, Low Dose Lx2006, Mid Dose Lx2006, High Dose Lx2006, Lx1001. These drug candidates are in various stages of clinical development as the company works toward FDA approval.